4 Minute Read
Nick Lynch, Partner of Federal Compliance Solutions (FCS) discusses insights into recent developments in pharmaceutical pricing, focusing on government programs like 340B, Medicaid Drug Rebate Program (MDRP), Medicare Part...
6 Minute Read
Read the latest on Industry Updates, Biosimilar Barriers, and the Impact of Drug Price Negotiations.
4 Minute Read
Read the latest on IRA implications on rare disease, economic challenges underpinning drug shortages, and navigating the 340B saga.
4 Minute Read
Read the latest on how states influence drug pricing and access, specialty pharmacies evolution to supoprt cell & gene therapies, and Walgreens entering the CGT arena.
3 Minute Read
Learn about the IRA's changes to Part D benefits have created uncertainty for both manufacturers and payers.
5 Minute Read
Discover the latest on IRA Part D Redesign Financial Implications, New Gene Therapies Give Newfound Hope for Patients, and Impact of Credit Card Fees in Government Pricing.
3 Minute Read
Discover the latest on the Pharmacy Reimbursements for CVS, FSS/IFF Reporting Alert, and the 340B Drug Discount Program.
5 Minute Read
Navigate market access issues with insights on 10 common warning signs, including outdated legacy mindsets, inadequate data sources, and operational silos.
5 Minute Read
Discover the latest on the FDA Approving Florida's Plan to Import Prescription Drugs from Canada, The GLP-1 Market Dilemma, and Illinois Price Gouging Law updates this month.